Cobazim

Quick links to important sections

Cobazim

Method of action: Antianemic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cobazim

Quick Facts

Property Description
Active Ingredient Cobamamide (Adenosylcobalamin)
Pharmacological Class Anti-anemic Agent, Vitamin B12 Group
Origin Derived Coenzyme Form (Metabolically Active Metabolite)
Dosage Forms Solution for Injection (Parenteral), Tablets (Oral)
General Purpose Support for DNA synthesis and Red Blood Cell Maturation

Cobazim: Classification and Definitional Identity

Cobazim is a pharmaceutical preparation classified as an Anti-anemic agent and belonging to the Vitamin B12 group (ATC Code B03BA04). Its active ingredient is Cobamamide, which is the internationally recognized nonproprietary name for Adenosylcobalamin or Dibencozide. This product is fundamentally defined as a coenzyme preparation because the active molecule is already in the specific structure required for biological activity within the body. The preparation is typically categorized as a prescription medicine and is available as a solution for injection for parenteral delivery or in tablet form for oral use.

Cobamamide: The Metabolically Active Form of Vitamin B12

The active substance, Cobamamide, is a derived coenzyme form; it is the naturally occurring metabolite of Vitamin B12 that is utilized predominantly within the cellular mitochondria. This structural specificity means it is chemically distinct from the precursor form, Cyanocobalamin, as it is an inherently metabolically active molecule, bypassing the body’s conversion steps. This active form is necessary as a cofactor for specific pathways crucial to cellular energy, a function utilized in metabolic processes.

General Purpose of the Coenzyme Preparation

The general purpose of this preparation is rooted in its function as an essential cofactor for a critical enzyme involved in metabolic rearrangement. By providing this specific coenzyme, Cobamamide ensures the efficient continuation of cellular energy pathways and supports the synthesis of healthy DNA, which is necessary for the proper maturation of red blood cells and the maintenance of nervous system function. This foundational support addresses the deficit of the activated B12 form, helping to ensure the integrity of the body's metabolic and hematopoietic processes.

What side effects are possible with Cobazim?

Possible Side Effects and Safety Information

The following is a summary of the officially documented adverse effects and safety characteristics for Cobamamide (Adenosylcobalamin) preparations, based strictly on government regulatory documents.

Adverse Reactions by System Organ Class

The adverse reactions listed in regulatory sources are classified based on the body systems affected. These categories include:

  • Immune System Disorders: Allergic reactions, including potentially severe systemic reactions.
  • Gastrointestinal Disorders: Effects such as nausea, vomiting, stomach pain, and diarrhea.
  • Nervous System Disorders: Non-specific effects like headaches and dizziness.
  • General Disorders and Administration Site Conditions: Localized reactions such as pain or discomfort at the injection site (specific to the injectable form).
Classification Adverse Reaction Example Frequency Classification
Serious Anaphylaxis (Severe Allergic Reaction) Rare
Common / Mild Gastrointestinal upset, Headache Mild/Common (or Incidence Not Known)
Common (Parenteral) Pain at the Injection Site Common

Safety Restrictions and Special Populations

The regulatory safety profile includes specific limitations and warnings for certain conditions and patient groups:

  • Contraindication: Known Hypersensitivity. The medicine is formally contraindicated in individuals with a known sensitivity or allergy to Cobalt or any form of Vitamin B12 (cobalamin), due to the risk of allergic reactions.
  • Leber's Hereditary Optic Atrophy (Leber's Disease): Caution is advised, and the use of cobalamin preparations is generally noted to be avoided in patients with this hereditary optic condition, as it may potentially aggravate the disorder.
  • Renal Impairment (Kidney Disease): Caution is advised, as impaired kidney function may affect the clearance of the vitamin, potentially leading to elevated levels and increasing the risk of adverse effects.

The official safety profile structures the understanding of risk by clearly defining a spectrum of adverse reactions, from common, mild, and non-specific effects to rare, serious immunological events. By explicitly listing constraints for known allergies and specific warnings for certain medical conditions, the regulatory profile sets boundaries for the medicine's use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Cobamamide (Adenosylcobalamin), an active form of Vitamin B12, characterizes it as a water-soluble compound with exceptionally low toxicity. Consequently, overdosage is generally not associated with specific toxic symptoms and is highly unlikely to be life-threatening.

Documented Overdose Manifestations

Feature Regulatory Description
Toxicity Profile Overdosage is typically not associated with specific toxic signs [NIH]; excess amounts are readily excreted via the urine [MedlinePlus].
Antidote Status No specific antidote is known for cobalamin overexposure, consistent with its low inherent toxicity [NIH].

Required Emergency Actions

Official labeling emphasizes that while severe complications from intrinsic toxicity are not a concern, seeking immediate medical attention or consulting a healthcare professional is the mandated action following any suspected overexposure. Treatment for uncomplicated overdosage is generally unlikely to be needed [EMA/MHRA regulatory guidance].

Urgent medical help must be sought immediately if a severe hypersensitivity or allergic reaction is suspected after administration. Signs such as difficulty breathing, swelling, or a rapid heart rate require emergency intervention [NIH], as these represent serious complications related to the route of administration, not toxic overdose.

Therapeutic Uses of Cobazim

Main Uses and Benefits of Cobazim

Cobazim is a therapeutic formulation of cobamamide, which is a bioactive coenzyme form of vitamin B12. Unlike cyanocobalamin, which requires conversion by the liver, cobamamide is metabolically active and plays a direct role in various physiological processes, particularly those involving protein metabolism and neurological health.

Treatment of Vitamin B12 Deficiency

The primary application of Cobazim is the correction of vitamin B12 deficiency. This condition can arise from nutritional gaps, malabsorption issues, or increased physiological demand. By restoring vitamin levels, it helps address the underlying cause of megaloblastic anemia, a condition where the bone marrow produces abnormally large, immature red blood cells that cannot function effectively.

Neurological Support

Cobamamide is essential for the maintenance of the nervous system. It is involved in the synthesis of myelin, the protective sheath that surrounds nerve fibers. Because of this role, Cobazim is often used to support recovery and management in cases of:

  • Peripheral Neuropathy: Nerve damage that can result in tingling, numbness, or weakness in the extremities.
  • Neuralgia: Intense, intermittent pain along the course of a nerve.
  • Optic Neuritis: Inflammation that damages the optic nerve.

Metabolic and Protein Synthesis Support

Cobazim is recognized for its protein-sparing effect and its role in stimulating protein synthesis. It participates in the metabolism of amino acids, which are the building blocks of body tissues. This metabolic support is beneficial in several clinical contexts:

  • Recovery and Convalescence: Assisting the body in rebuilding tissues following surgery, severe illness, or injury.
  • Growth Support: Used in pediatrics to address growth delays or failure to thrive when linked to metabolic insufficiency or vitamin deficiency.
  • Physical Debility: Supporting patients experiencing generalized weakness, fatigue, or unintended weight loss by improving the body's ability to utilize nutrients efficiently.

Liver Function Support

In some therapeutic contexts, cobamamide is utilized to support liver health. It aids in the metabolic processes within hepatocytes, contributing to the overall management of hepatic disorders where vitamin B12 utilization may be impaired.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cobazim?

Eligibility for Cobazim (Cobamamide/Adenosylcobalamin) is strictly defined by official regulatory documentation, focusing on contraindications and specific population limitations.

Contraindications (Who Must Not Use)

Classification Population/Condition
Absolute Prohibition Patients with known hypersensitivity to Cobamamide, Vitamin B12, or Cobalt.
Disease Prohibition Patients diagnosed with Early Leber's Disease (hereditary optic atrophy).

Age and Condition Restrictions

  • Pediatric Limitations: Use in children, particularly those under 11 to 12 years of age, is often not established or contraindicated in certain formulations due to insufficient safety data. Standard use is typically for adults.
  • Organ Impairment: Conditional use or caution is required for patients with severe renal (kidney) or hepatic (liver) impairment, especially with high-dose preparations.
  • Pregnancy and Lactation: Use may be permitted for treating an established deficiency under a physician’s guidance, and it is generally considered compatible with breastfeeding.
  • Hematological Restriction: Patients with Megaloblastic Anemia must be carefully monitored for coexisting Folate Deficiency, as B12 treatment alone can mask the true deficiency, requiring conditional co-management.

What should I know about interactions with other medicines?

Cobazim’s official interaction profile is structured around documented constraints affecting the B12 moiety’s exposure and therapeutic response. No combinations are formally classified as contraindicated in regulatory labeling.

Exposure-Altering Interactions

Several medicinal products and substances are officially documented to reduce the intestinal absorption of Vitamin B12, thereby lowering its bioavailability. These include Gastric Acid Inhibitors (e.g., proton pump inhibitors and H2-blockers), which interfere with the acid-dependent release of the vitamin from food. Other substances that may impair absorption include the antidiabetic agent Metformin, the antigout agent Colchicine, and the antituberculosis drug Para-aminosalicylic Acid. Heavy alcohol intake maintained for longer than two weeks is also formally documented to produce malabsorption.

Response-Modifying Interactions

The therapeutic effect may be blunted by co-administration with bone marrow suppressant drugs such as Chloramphenicol, which antagonizes the hematopoietic response. High doses of Folic Acid are documented to mask the hematologic signs of B12 deficiency without preventing neurological damage. Furthermore, certain Antibiotics, Methotrexate, and Pyrimethamine are documented to invalidate diagnostic blood assays used to measure B12 and folate levels.

Population-Specific Constraint

A documented population-specific constraint relates to injectable B12 forms: patients with renal impairment may face a risk of aluminum accumulation and toxicity associated with aluminum content present in some formulations.

Mechanism of Action

Mitochondrial Enzyme Activation and Cofactor Role

The molecule's action involves its active form, Adenosylcobalamin (Cobamamide), functioning as a cofactor to activate the enzyme Methylmalonyl-CoA mutase (MCM) within the cell's mitochondria. By supplying this molecule in its pre-formed coenzyme state, the mechanism directly initiates the enzyme's essential catalytic function.


Correction of Metabolic Flux and Metabolite Modulation

Activation of MCM catalyzes the conversion of L-methylmalonyl-CoA into succinyl-CoA, thereby influencing metabolic flow and contributing an intermediate to the cell's energy cycle. This conversion modulates the concentration of methylmalonic acid (MMA), a metabolite whose accumulation is associated with alterations to nerve fiber structure.


Physiological Support for Cell Maturation

The mechanism's systemic effect relates to maintaining the metabolic conditions required for high cellular activity. By supporting the production of succinyl-CoA, the mechanism maintains the metabolic conditions required for the proliferation and maturation of blood cell precursors in the bone marrow.

Dosage and Administration Information

How Cobazim Is Used: Official Usage Principles

Cobazim (Cobamamide) is typically used according to a two-phase regimen designed to address vitamin B12 deficiency, particularly in cases involving chronic malabsorption. This involves an initial intensive phase to correct the deficiency followed by a long-term maintenance phase.


Administration Routes and Dosing Regimens

The route of administration is a critical component of initial therapy to bypass potential absorption issues. The preferred parenteral routes are Intramuscular (IM) injection or Subcutaneous (SC) injection. The Intravenous (IV) route is avoided as it leads to minimal body retention and rapid urinary loss of the compound.

Usage Phase Dosing Range & Frequency Key Procedural Condition
Initial Correction 250 to 1,000 micrograms per dose, administered daily or on alternate days for one to two weeks. Injection must be administered slowly (IM/SC). Solution can be warmed before use.
Long-Term Maintenance 1,000 micrograms per dose, administered monthly or every two to three months (parenteral) or 300 micrograms daily (oral). Treatment for certain conditions, such as Pernicious Anemia, is established as lifelong.

Contextual Instructions

When the oral tablet form is used for long-term maintenance, the tablets are generally taken between meals or approximately one hour after a meal. For pediatric patients, specialized initial and maintenance regimens are specified in the product labeling, while older adults generally use the standard adult dosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cobamamide

Evidence for Anemia and Metabolic Correction

Clinical research, including Randomized Controlled Trials (RCTs) and systematic reviews, has examined B12 replacement therapy for addressing anemia linked to deficiency, such as Pernicious Anemia. These studies monitor hematologic parameters (like blood cell counts) and the normalization of key metabolic biomarkers. Findings describe consistent patterns related to these changes in study populations. However, the specific research landscape features limited head-to-head RCTs comparing the long-term effects of the Cobamamide form directly against other B12 active forms.


Neurological Symptoms and Functional Outcomes

Research has utilized RCTs to examine B12 replacement in the context of neurological signs, such as numbness and tingling. Studies explored changes in neuropathy symptom scores and objective measures like Nerve Conduction Velocities. Reported changes in sensory symptoms were measured, but findings are often mixed or inconsistent regarding objective measures. Limited information exists regarding the full long-term functional recovery for all nerve-related symptoms, with follow-up durations restricted in many high-quality trials.


Routes of Administration and Uncertainty

Comparative studies have explored the performance of oral versus parenteral (injection) routes. Findings indicate that large-dose oral B12 was associated with similar patterns of biomarker changes and blood level increases compared to intramuscular injection in certain adult deficiency cases.

The evidence base highlights that extended, continuous monitoring was utilized in studies for chronic conditions. Evidence quality varies across studies, and certainty remains low for comprehensive long-term neurological recovery across all designs. Data for specific subgroups, such as children or certain comorbid populations, also remains insufficient or focused only on short-term outcomes.

Key Studies & References

  1. Systematic Review and Pragmatic Clinical Approach to Oral and Nasal Vitamin B12 (Cobalamin) Treatment in Patients with Vitamin B12 Deficiency Related to Gastrointestinal Disorders
  2. Oral Vitamin B12 Replacement for the Treatment of Pernicious Anemia
  3. Vitamin B12 deficiency in over 16s: diagnosis and management (NICE Guideline NG239)
  4. Association of vitamin B12, methylmalonic acid, and functional parameters (Focus on biomarkers and deficiency diagnosis)

Frequently Asked Questions (FAQ)

Common questions about Cobazim (FAQ)


Q: Is Cobazim the same as other products often mentioned for similar health goals?

Official documents clarify that Cobazim (Cobamamide) is a specific, metabolically active form of Vitamin B12. This structure is distinct from precursor forms like Cyanocobalamin. The product is defined as a coenzyme preparation, meaning the active molecule is already in the form required for biological use.

Q: How long does it usually take to notice anything after starting Cobazim?

Studies have examined the time required for clinical parameters, such as metabolic biomarkers and blood cell counts, to begin normalizing after treatment starts. Official product information does not explicitly define a typical timeline for when an individual patient might observe a change in symptoms.

Q: Are there any food items or beverages I should avoid while taking Cobazim?

Official guidance notes that sustained heavy alcohol intake for over two weeks may affect the body's absorption of the vitamin. For the oral tablet form, administration is usually recommended to occur between meals or about one hour after a meal.

Q: What is the difference between Cobazim and the B-vitamin complex my friend takes?

Cobazim is specifically the metabolically active form of Vitamin B12, known as Cobamamide. This structure is supplied to bypass the conversion steps typically required for other forms of B12 to become metabolically active. Most official product information focuses on this unique structural and functional distinction.

Q: Is Cobazim safe to take if I am already managing a long-term condition?

Official documentation strictly defines specific long-term conditions where use is contraindicated, such as Early Leber's Disease. Caution and careful monitoring are advised for patients who have severe kidney or liver impairment. Reviewing existing conditions with a healthcare professional is consistent with official guidance, particularly regarding the complete product label.

Q: Why do some people mention Cobazim for 'energy' when official sources don't list it as an energy pill?

Official sources do not classify Cobazim as an 'energy pill,' but its mechanism of action is linked to cellular metabolism. The molecule supports a critical pathway that contributes an intermediate to the cell's essential energy production cycle. This fundamental role in metabolism may be the reason for its association with energy in general discussions.

Q: Does my diet need to change when I start taking Cobazim?

According to regulatory documents, a key interaction involves heavy alcohol intake, which may impair the absorption of the vitamin if maintained for more than two weeks. Aside from specific timing for oral tablets (between or after meals), no generalized dietary changes are typically outlined in the official guidance.

Q: How quickly does Cobazim start working inside the body after taking it?

Studies track the rate at which treatment is associated with changes in metabolic biomarkers and blood cell parameters within the body. Official documentation and research do not typically define a set timeline for when an individual patient might observe a change in symptoms.

Q: What are the signs that Cobazim might not be working for someone?

The effectiveness of Cobazim is assessed by clinical and laboratory parameters, such as the normalization of hematologic status and metabolic biomarkers. If a patient’s original symptoms related to Vitamin B12 deficiency persist or worsen, this may be an indicator of a lack of therapeutic response, a matter for professional review.

Q: Does taking Cobazim impact my ability to drive or use machinery?

The regulatory safety profile includes non-specific nervous system effects, such as dizziness and headaches. Caution is warranted if a patient experiences these effects, as the symptoms may impair the ability to safely drive or operate machinery.

Q: What makes Cobazim suitable for specific groups of people?

The molecular structure of Cobazim is the pre-formed, active coenzyme form (Adenosylcobalamin). This design allows the necessary molecule to be available for cellular function immediately, bypassing the body's internal conversion steps required for other Vitamin B12 precursors. This can be suitable for individuals who have issues with these conversion pathways.

Q: Are there any long-term safety concerns associated with taking Cobazim for many years?

According to regulatory documentation, a specific long-term constraint relates to the injectable forms. Patients with renal impairment (kidney disease) face a potential risk of aluminum accumulation and toxicity over long periods, which is linked to the aluminum content in some formulations.

Q: Does the efficacy of Cobazim vary based on the user's age or weight?

Official information defines specific limitations for use in younger children, often noting insufficient safety data for those under 11 to 12 years of age. For older adults, regulatory guidance indicates that they generally use the same standard adult dosing regimen.

Q: Is Cobazim the kind of drug that can be suddenly stopped or needs to be tapered?

Official guidance on certain chronic deficiency conditions, such as Pernicious Anemia, establishes the treatment as a lifelong necessity. This implies that for these conditions, the product is not intended to be stopped or tapered. Consultation with a healthcare professional is necessary before making any changes to a treatment plan.

Q: Why is it important to check drug interactions for Cobazim?

It is important to check drug interactions because certain substances are documented to affect the efficacy of Cobazim. Some interactions can reduce the absorption and lower the overall bioavailability of the vitamin. Other interactions may potentially blunt the expected therapeutic response in the bone marrow.

Q: What happens if I accidentally miss a day of Cobazim?

The official regulatory labeling for the product typically includes specific instructions detailing the procedure for a patient who forgets a single dose. These instructions outline the appropriate non-clinical steps to follow if a dose is missed.

Q: Why is Cobazim sometimes described as a 'pro-vitamin'?

Official documents define Cobamamide as a derived coenzyme form or a metabolically active metabolite. The term 'pro-vitamin' is non-official but may be used to convey that the molecule is an essential, readily usable form.

Q: How is Cobazim removed from the body?

Regulatory documents include standard pharmacokinetic information outlining how the molecule is processed after administration. This information details the body's natural route of excretion and the typical clearance rate of the molecule.

Q: What should I do if a potential side effect of Cobazim continues for several days?

Official regulatory patient information directs that a healthcare professional should be contacted or consulted if a side effect or symptom persists or becomes troublesome. This ensures the symptom is evaluated in the context of the patient's overall health and treatment plan.

Q: What is the typical time frame for the expected duration of Cobazim's effects?

Official regulatory documents contain standard information about the molecule's duration of action. This pharmacokinetic data outlines the expected time frame for the therapeutic effects to last following administration.

Q: What if I experience a rare side effect mentioned in the documentation?

Official patient documentation explicitly states that for rare, serious adverse events, such as an allergic reaction like anaphylaxis, immediate medical attention should be sought. The safety profile clearly defines the spectrum of risks, from common to rare and serious events.

How should Cobazim be stored and disposed of?

How to Store and Dispose of Cobazim?

Cobazim (Cobamamide) requires specific storage and handling as defined by regulatory labeling to maintain the stability of the active coenzyme. All forms of the medicine must be stored at a controlled room temperature, typically below 25 C (77 F), and must be strictly protected from light by remaining in the original outer carton.

Key Storage Constraints

  • Do not freeze the product, as this can damage the solution and container.
  • Keep the medicine out of the sight and reach of children.

Disposal Requirements

Unused or expired medicine must not be disposed of via household waste or wastewater. For the injectable form, used needles and syringes must be placed immediately into a designated sharps container and managed according to local regulations for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cobazim found in:

A-Z Index: